Novavax (NVAX) 10-K2018 FY Annual report

Filed: 18 Mar 19, 4:31pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: amplified, apportionment, array, attending, Biovitrum, carryforward, conflicting, EMA, entitled, explanatory, flat, flu, Fluzone, GDPR, greatly, highlight, impactthat, importantly, Intravaac, Janssen, job, King, LRTI, MAA, marginal, migration, mindful, Moderna, NanoFluTM, Notwithstanding, nucleic, offshore, Orphan, paragraph, pattern, percent, preceding, prefusogenic, PTA, Rachel, ready, receipt, repatriated, Restoration, ResVax, ResVaxTM, spent, stand, supersede, taxation, Vice, viewed

Removed: absolutely, acute, ad, administered, adult, affiliate, Africa, aged, ahead, al, Allergy, amino, antigenic, approximated, ascending, assembly, attributed, Australia, averaged, Barclay, baseline, began, biogeneric, biotech, blood, Boyce, breathing, broaden, broader, called, calling, Canada, case, cdc, ceased, cGMP, Child, cohort, collected, continuously, contrast, copy, delivered, diagnostic, differentiating, Dis, dosing, EBOV, ELISA, epidemic, Epidemiol, examined, executed, expanding, expedite, expeditiously, exposing, extrapolated, facilitate, Falsey, Fast, fatal, fatality, fever, fewer, finally, France, geometric, Germany, Glezen, glycoprotein, guaranteed, Hall, hemorrhagic, hoc, holding, ideal, IgG, immunized, immunogenic, induced, induction, infant, infect, institute, intensified, intramuscular, intranasal, Italy, JID, Lancet, lethal, lifelong, literature, Makona, master, MedImmune, microneutralization, microneutralizing, mild, monovalent, morbidity, mortality, mother, multivalent, Nair, NE, NEJM, neutralize, NewLink, ninety, October, optimized, original, owed, Oxford, path, payor, PCA, Pediatr, placebo, presence, primate, promise, proportion, proportional, proven, quickly, randomized, regimen, regularly, repeat, Resolution, restructured, rollover, room, Satellite, sequential, serum, slightly, Spain, specificity, stable, statistically, Stockman, Street, sublicense, subset, sufficiency, susceptibility, symptomatic, territory, tested, transplacental, uk, unadjuvanted, unique, unmet, upfront, USA, vaccinated, vector, vested, viable, visibility, Washington, Weekly, West

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated NVAX transcripts

NVAX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)

Registration Statement (Form S-8 No. 333-226498) pertaining to the Novavax, Inc. stock incentive plan and 2013 employee stock purchase plan,

(2)

Registration Statement (Form S-3 No. 333-222365) pertaining to Novavax, Inc. common stock,

(3)

Registration Statement (Form S-3 No. 333-215389) pertaining to Novavax, Inc. common stock,

(4)

Registration Statement (Form S-8 No. 333-219829) pertaining to the Novavax, Inc. stock incentive plan,

(5)

Registration Statement (Form S-8 No. 333-213069) pertaining to the Novavax, Inc. stock incentive plan and 2013 employee stock purchase plan,

(6)

Registration Statement (Form S-8 No. 333-206354) pertaining to the Novavax, Inc. stock incentive plan,

(7)

Registration Statement (Form S-8 No. 333-198121) pertaining to the Novavax, Inc. stock incentive plan,

(8)

Registration Statement (Form S-8 No. 333-190600) pertaining to the Novavax, Inc. stock incentive plan,

(9)

Registration Statement (Form S-8 No. 333-190599) pertaining to the Novavax, Inc. 2013 employee stock purchase plan,

(10)

Registration Statement (Form S-8 No. 333-183113) pertaining to the Novavax, Inc. stock incentive plan,

(11)

Registration Statement (Form S-8 No. 333-145298) pertaining to the Novavax, Inc. stock incentive plan,

(12)

Registration Statement (Form S-8 No. 333-130990) pertaining to the Novavax, Inc. stock incentive plan,

(13)

Registration Statement (Form S-8 No. 333-110401) pertaining to the Novavax, Inc. stock incentive plan,

(14)

Registration Statement (Form S-8 No. 333-97931) pertaining to the Novavax, Inc. stock incentive plan,

(15)

Registration Statement (Form S-8 No. 333-46000) pertaining to the Novavax, Inc. stock incentive plan,

(16)

Registration Statement (Form S-8 No. 333-77611) pertaining to the Novavax, Inc. stock incentive plan,

(17)

Registration Statement (Form S-8 No. 333-03384) pertaining to the Novavax, Inc. stock incentive plan

(18)

Registration Statement (Form S-8 No. 33-80279) pertaining to the Novavax, Inc. stock incentive plan, and

(19)

Registration Statement (Form S-8 No. 33-80277) pertaining to the Novavax, Inc. stock incentive plan

of our reports dated March 18, 2019, with respect to the consolidated financial statements of Novavax, Inc., and the effectiveness of internal control over financial reporting of Novavax, Inc., included in this Annual Report (Form 10-K) of Novavax, Inc. for the year ended December 31, 2018.

/s/ Ernst & Young LLP

Baltimore, Maryland

March 18, 2019

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.